Skip to content

Study · In vitro (cells) · 2005

4 results

Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.

Goursaud S, Pineau N, Becq-Giraudon L, Gressens P, Muller JM, Janet T

Journal of neuroimmunology1 Jan 2005Cited by 8 (Europe PMC)

PMID15589042 (opens in a new tab)DOI10.1016/j.jneuroim.2004.08.018 (opens in a new tab)PepBankPUB-15589042
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human H9 lymphoblastoma cells, VIP stimulated proliferation, by a mechanism that differed from that of PHM.

    In plain wordsIn lab-grown human lymphoma cells, VIP made the cells multiply, and it did so differently from a related peptide, PHM.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseH9 cell proliferation
    Study

    humann: not reported in source

    H9 human lymphoblastoma cell line
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The proliferation of human lymphoblastoma cell line (H9) was differently stimulated by Peptide Histidine Methionine (PHM) and Vasoactive Intestinal Peptide (VIP).
  2. 02LabIn vitro (cells)Mechanism

    In H9 cells, the mitogenic activity of VIP was sensitive to Pertussis toxin and insensitive to adenylate cyclase inhibitors.

    In plain wordsIn lab-grown human lymphoma cells, VIP-driven growth depended on a pertussis toxin-sensitive pathway, not on the adenylate cyclase pathway.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSignalling pathway of VIP mitogenic activity
    Study

    humann: not reported in source

    H9 human lymphoblastoma cell line
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VIP mitogenic activity was Pertussis toxin (PTX) sensitive and AC inhibitors insensitive.
  3. 03LabIn vitro (cells)Activity measurement

    In H9 cell membranes, pharmacological experiments indicated both GTP-insensitive and GTP-sensitive high-affinity PHM/VIP binding sites.

    In plain wordsIn lab tests on human lymphoma cell membranes, VIP and PHM bound to two kinds of high-affinity sites.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicablePHM/VIP high-affinity binding sites on H9 membranes
    Study

    humann: not reported in source

    H9 human lymphoblastoma cell line
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacological experiments performed on H9 membranes with or without a GTP analogue indicated expression of both GTP-insensitive and -sensitive PHM/VIP high-affinity binding sites (HA).

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In H9 cells, the VPAC1 antagonist VIP(10-28) bound all GTP-insensitive PHM sites and inhibited the mitogenic actions of PHM and VIP evenly.

    In plain wordsIn lab-grown human lymphoma cells, a VIP fragment that blocks the VPAC1 receptor reduced growth caused by both PHM and VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseInhibition of PHM and VIP mitogenic actions by VIP(10-28)
    Study

    humann: not reported in source

    H9 human lymphoblastoma cell line
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    VIP(10-28), known as a VPAC1 antagonist, bond to all GTP-insensitive PHM sites and inhibited evenly the PHM and VIP mitogenic actions.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.